In Vitro Investigation of Binding Interactions between Albumin–Gliclazide Model and Typical Hypotensive Drugs

Zurawska-Plaksej, Ewa; Wiglusz, Rafal; Piwowar, Agnieszka; Wiglusz, Katarzyna

doi:10.3390/ijms23010286

Open AccessArticle

In Vitro Investigation of Binding Interactions between Albumin–Gliclazide Model and Typical Hypotensive Drugs

¹

Department of Toxicology, Wroclaw Medical University, 50-556 Wroclaw, Poland

²

Institute of Low Temperature and Structure Research, Polish Academy of Sciences, 50-422 Wroclaw, Poland

³

Department of Analytical Chemistry, Wroclaw Medical University, 50-556 Wroclaw, Poland

^*

Author to whom correspondence should be addressed.

Int. J. Mol. Sci. 2022, 23(1), 286; https://doi.org/10.3390/ijms23010286

Submission received: 3 December 2021 / Revised: 20 December 2021 / Accepted: 26 December 2021 / Published: 28 December 2021

(This article belongs to the Special Issue Protein-Protein and Protein-Ligand Interactions: Current Challenges and Perspectives)

Download

Browse Figures

Versions Notes

Abstract

Type 2 diabetes management usually requires polytherapy, which increases the risk of drug-to-drug interactions. Among the multiple diabetes comorbidities, hypertension is the most prevalent. This study aimed to investigate the binding interactions between the model protein, bovine albumin, and the hypoglycemic agent gliclazide (GLICL) in the presence of typical hypotensive drugs: quinapril hydrochloride (QUI), valsartan (VAL), furosemide (FUR), amlodipine besylate (AML), and atenolol (ATN). Spectroscopic techniques (fluorescence quenching, circular dichroism) and thermodynamic experiments were employed. The binding of the gliclazide to the albumin molecule was affected by the presence of an additional drug ligand, which was reflected by the reduced binding constant of the BSA–DRUG–GLICL system. This may indicate a possible GLICL displacement and its enhanced pharmacological effect, as manifested in clinical practice. The analysis of the thermodynamic parameters indicated the spontaneity of the reaction and emphasized the role of hydrogen bonding and van der Waals forces in these interactions. The secondary structure of the BSA remained almost unaffected.

Keywords: bovine serum albumin; gliclazide; quinapril; valsartan; furosemide; amlodipine; atenolol; albumin–drug interactions; type 2 diabetes; hypertension

Share and Cite

MDPI and ACS Style

Zurawska-Plaksej, E.; Wiglusz, R.; Piwowar, A.; Wiglusz, K. In Vitro Investigation of Binding Interactions between Albumin–Gliclazide Model and Typical Hypotensive Drugs. Int. J. Mol. Sci. 2022, 23, 286. https://doi.org/10.3390/ijms23010286

AMA Style

Zurawska-Plaksej E, Wiglusz R, Piwowar A, Wiglusz K. In Vitro Investigation of Binding Interactions between Albumin–Gliclazide Model and Typical Hypotensive Drugs. International Journal of Molecular Sciences. 2022; 23(1):286. https://doi.org/10.3390/ijms23010286

Chicago/Turabian Style

Zurawska-Plaksej, Ewa, Rafal Wiglusz, Agnieszka Piwowar, and Katarzyna Wiglusz. 2022. "In Vitro Investigation of Binding Interactions between Albumin–Gliclazide Model and Typical Hypotensive Drugs" International Journal of Molecular Sciences 23, no. 1: 286. https://doi.org/10.3390/ijms23010286

APA Style

Zurawska-Plaksej, E., Wiglusz, R., Piwowar, A., & Wiglusz, K. (2022). In Vitro Investigation of Binding Interactions between Albumin–Gliclazide Model and Typical Hypotensive Drugs. International Journal of Molecular Sciences, 23(1), 286. https://doi.org/10.3390/ijms23010286

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Menu

In Vitro Investigation of Binding Interactions between Albumin–Gliclazide Model and Typical Hypotensive Drugs

Abstract

Share and Cite

Article Metrics

Article Access Statistics

Further Information

Guidelines

MDPI Initiatives

Follow MDPI